Table 2 Baseline characteristics for patients treated with high‐intensity and moderate‐intensity statins.
| Characteristic | Entire cohort | Propensity‐matched cohort | ||
|---|---|---|---|---|
| High‐intensity statin users (n = 3066) | Moderate‐intensity statin users (n = 15245) | High‐intensity statin users (n = 3062) | Moderate‐intensity statin users (n = 3062) | |
| Demographics | ||||
| Median age, years | 77 | 78 | 77 | 77 |
| Female, % | 76.0 | 75.8 | 76.0 | 75.2 |
| Comorbid conditions, % | ||||
| Prior acute coronary syndrome | 4.5 | 6.2 | 4.5 | 4.6 |
| Congestive heart failure | 60.7 | 59.5 | 60.6 | 60.7 |
| Cerebrovascular disease | 41.2 | 40.4 | 41.2 | 41.8 |
| Peripheral vascular disease | 32.5 | 29.4 | 32.4 | 31.8 |
| Hypertension | 85.6 | 83.6 | 85.6 | 85.3 |
| Diabetes | 55.5 | 49.8 | 55.4 | 56.7 |
| Chronic kidney disease | 34.1 | 30.9 | 34.0 | 34.3 |
| Chronic obstructive pulmonary disease | 42.6 | 40.5 | 42.6 | 43.3 |
| Malignancy | 7.1 | 6.3 | 7.1 | 6.7 |
| Dementia | 9.7 | 10.2 | 9.7 | 9.8 |
| Concurrent medication use, % | ||||
| Prior statin | 72.9 | 60.9 | 72.8 | 72.5 |
| ACE inhibitor or angiotensin II receptor blocker | 58.7 | 53.9 | 58.7 | 59.0 |
| Clopidogrel | 30.1 | 23.4 | 30.1 | 30.6 |
| β‐blocker | 67.0 | 61.5 | 67.0 | 67.7 |
| Calcium‐channel blocker | 49.4 | 50.3 | 49.3 | 50.2 |
| Diuretics | 16.8 | 14.1 | 16.8 | 16.2 |
| Nitrates | 58.7 | 59.1 | 58.7 | 58.8 |
| Warfarin | 17.9 | 16.7 | 17.9 | 18.4 |
| Procedures on index hospitalisation | ||||
| Angiography | 47.8 | 45.4 | 47.8 | 47.7 |
| Angioplasty | 2.9 | 4.2 | 2.9 | 3.4 |
| Stent insertion | 18.4 | 14.3 | 18.3 | 17.8 |
| Bypass surgery | 9.7 | 10.5 | 9.7 | 9.2 |
| Median length of hospital stay, days | 5 | 5 | 5 | 5 |
| Median (IQR) length of follow‐up, days | 487 (211–1018) | 633 (245–1276) | 488 (211–1022) | 529 (228–1005) |
| Median (IQR) number of days between discharge and prescription | 16 (3–34) | 15 (2–33) | 16 (3–34) | 16 (3–34) |
IQR, interquartile range (25th–75th centiles).